Atomo Diagnostics Showcases Innovative User-Centered Rapid Diagnostic Tests at Arab Health

Atomo Diagnostics (Sydney, Australia) is showcasing its range of innovative, user-centered rapid diagnostic test platforms at Arab Health 2023. The Arab Health Exhibition & Congress is taking place from 30 January – 2 February 2023 at the Dubai Convention and Exhibition Center. Atomo is part of the ABHI UK Pavilion where it is demonstrating how the company’s simple and low-cost solutions can deliver better user experience, more accurate results and better healthcare outcomes.

Atomo is the world’s first company to introduce human-centered engineering to the heart of diagnostics design. The company has developed a unique technology based on the philosophy that fast, accurate point of care testing should be simple and intuitive, focusing on how diagnostic tests operate in the hands of users to improve ease of use and reduce error rates. Atomo has created devices that address the problems commonly associated with standard multi-component rapid diagnostic test kits that have also received several international design awards.

Atomo’s Rapid Diagnostic Test (RDT) platforms offer all-in-one convenience with a built-in safety lancet, unique sample collection feature, single action sample and buffer delivery system, and interlocked user steps. The innovative design and built-in features of Atomo’s products are designed to make them simpler to use than standard multi-component test kits, with less scope for user errors. The company offers the world’s first integrated, blood-based rapid diagnostic test (RDT) for HIV screening, recognized globally for its design, performance and ease-of-use, with an accuracy of 99.6%.

Atomo’s extensive product range also encompasses accurate point of care diagnostic platforms that can be used in testing for infectious diseases such as COVID-19, allergy sensitivities, wellness, women’s health, men’s health, sexual health, heart health and other applications. Atomo recently introduced a Swab Platform to market, which expands its product range beyond blood-based testing and has been developed to improve usability and performance of traditional swab-based rapid tests. The company’s products are approved for distribution in over 40 countries.

“Our innovative rapid test solutions deliver unmatched usability and simplicity in point-of-care testing, and have demonstrated excellent performance for both professional and home use. Our flagship HIV Self Test is prequalified by the WHO and registered in more than 20 countries. Beyond HIV, Atomo works with partners to commercialize tests on its devices for other applications, with commercialized tests delivering early detection of pregnancy and differentiating between viral and bacterial infection in primary care settings,” said John Kelly, CEO of Atomo Diagnostics. “Our unique devices and functionality are increasingly being recognized as a solution to decentralized testing needs and we continue to seek partners looking to improve the usability and performance of their POC tests. We are excited to be joining ABHI at this year’s Arab Health Exhibition where we look forward to showcasing our innovative products and technologies, as well as making new connections and forming new partnerships with global distributors.”

Related Links:
Atomo Diagnostics

Visit expo >

Gold Member

STI Test

Vivalytic Sexually Transmitted Infection (STI) Array

Antipsychotic TDM Assays
Saladax Antipsychotic Assays

New

Resorbable Bovine Collagen Membrane

GenDerm

New

Immobilization System

Cranial 4Pi Immobilization